This article previews a news piece about new clinical trial results for a tau-targeting Alzheimer’s therapy, highlighting study type and implications for the field.
Key Takeaways
- Diranersen slowed decline on CDR-SB across all dose groups compared with placebo
- 60 mg intrathecal dose showed a 26% CDR-SB slowing and larger cognitive effects at 18 months
- CSF total tau fell 50–65% and tau PET signals decreased across evaluated brain regions